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ABSTRACT
The Drosophila mophogenetic protein Bicoid
(Bcd) can activate transcription in a concentration-
dependent manner in embryos. It contains a self-
inhibitory domain that can interact with the
co-repressor Sin3A. In this report, we study a Bcd
mutant, Bcd(A57–61), which has a strengthened
self-inhibitory function and is unable to activate
the hb-CAT reporter in Drosophila cells, to analyze
the role of co-factors in regulating Bcd function.
We show that increased concentrations of the co-
activator dCBP in cells can switch this protein from
its inactive state to an active state on the hb-CAT
reporter. The C-terminal portion of Bcd(A57–61) is
required to mediate such activity-rescuing function
of dCBP. Although capable of binding to DNA
in vitro, Bcd(A57–61) is unable to access the hb
enhancer element in cells, suggesting that its DNA
binding defect is only manifested in a cellular con-
text. Increased concentrations of dCBP restore not
only the ability of Bcd(A57–61) to access the hb
enhancer element in cells but also the occupancy of
the general transcription factors TBP and TFIIB at the
reporter promoter. These and other results suggest
that an activator can undergo switches between its
activeandinactivestatesthroughsensingtheoppos-
ing actions of positive and negative co-factors.
INTRODUCTION
Regulation of gene transcription plays a critical role in many
biological processes that range from cell growth and differ-
entiation to embryonic patterning (1,2). Genes that participate
in these biological processes need to be speciﬁcally turned on
or off by transcription factors at the appropriate time and
location. It is becoming increasingly clear that many trans-
cription factors can act as both activators and repressors
in a context-dependent manner [reviewed in (3)]. Promoter/
enhancer architecture and cellular levels of other proteins have
been suggested to play roles in inﬂuencing a transcription
factor’s regulatory functions, but the precise mechanisms in
most cases remain largely unclear. For proteins that can work
as both activators and repressors, they have three distinct
activity states: active, repressive and inactive (neither active
nor repressive). In contrast, for proteins that work only as acti-
vators, such as the Drosophila protein Bicoid (Bcd), they only
have two activity states: active and inactive. Analysis of these
proteins can thus help us understand the important question
of how the simple on–off switches of activator activities are
achieved. Bcd is a well-documented protein that undergoes
such on–off activity switches in a concentration-dependent
manner (see below). The experiments described here suggest
another mechanism in which the opposing actions of positive
and negative co-factors can facilitate Bcd to switch between
its active and inactive states in a manner that is independent
of Bcd concentration.
Bcd is a molecular morphogen that plays a critical role in
patterning embryonic structures, including the head and thorax
(4,5). This 489 amino acids transcription factor contains a
homeodomain (residues 92–151) in its N-terminal portion (6).
Bcd, which is distributed in the early embryo as an anterior-
to-posterior gradient, is responsible for activating speciﬁc tar-
get genes in a concentration-dependent manner. For example,
orthodenticle (otd), hunchback (hb) and knirps (kni) are direct
Bcd target genes that are required for patterning the head,
thoracic and abdominal structures, respectively (7). These
genes are expressed in distinct parts of the embryo by respond-
ing to different Bcd concentrations (8–10). Bcd has the ability
to bind DNA in a highly cooperative manner (11–14), and it
has been suggested that the afﬁnity of Bcd binding sites in an
enhancer can determine the concentration of Bcd required
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doi:10.1093/nar/gki691for activating transcription (9,15,16). Our recent studies sug-
gest that the arrangements of Bcd binding sites in an enhancer
canalsoplayacriticalroleinregulatingtheactivityofBcdand
contributing to its concentration-dependent action (17).
CBP is a co-activator that interacts with many transcription
factors and participates in the activation process (18,19).
Its histone acetyltransferase (HAT) enzymatic activity is
thought to alter chromatin structure by acetylating the histone
tails thus increasing the accessibility of DNA for both gene-
speciﬁc transcription factors and general transcription factors
(GTFs). CBP can also play a structural role by bridging
between transcription factors and GTFs or by recruiting
other HAT activities (18,19). In Drosophila, dCBP has been
shown to be a co-activator for Ci (20), Mad (21) and Dorsal
(22). dCBP also plays a role in facilitating Bcd to activate
transcription (23). dCBP and Bcd can interact with each other
through distinct domains on different enhancers. In particular,
on the hb enhancer element the C-terminal portion of Bcd
plays an important role in responding to the co-activation
function of dCBP, whereas on the kni enhancer element, the
N-terminal domain plays an important role (23).
In addition to its ability to interact with co-activators, such
as dCBP, Bcd can also interact with co-repressors. An analysis
of the N-terminal region of Bcd revealed a self-inhibitory
domain (residues 52–91) that can dramatically inhibit the abil-
ity of Bcd to activate transcription (24). For example, on the
hb-CAT reporter gene which contains the Bcd-responsive
hb enhancer element, a Bcd derivative lacking the entire
N-terminal domain, Bcd(92–489), exhibits an activity 40
times higher than the full-length protein in Drosophila S2
cells. A systematic analysis of the self-inhibitory domain
identiﬁed a 10 amino acid motif (residues 52–61) that is
most critical for the self-inhibitory function. Interestingly,
mutations of different residues in this motif can cause dras-
tically opposing effects (25). In particular, the mutant protein
Bcd(A52–56), which has residues 52–56 changed to alanines,
is 25 times more active than wt Bcd on the hb-CAT reporter
in S2 cells. In contrast, on the same reporter another mutant,
Bcd(A57–61), which has the neighboring ﬁve amino acids
changed to alanines, is virtually inactive (<2% of wt Bcd
activity) at all concentrations. The co-repressor Sin3A has
been shown to interact with the evolutionarily conserved
N-terminal domain of Bcd, and it is proposed that mutations
that alter the 10 amino acid motif can weaken or strengthen
this interaction, thus increasing or decreasing, respectively,
the activity of Bcd (25). Another component of the Sin3A-
HDAC (histone deacetylase) complex, SAP18, has also been
shown to interact with Bcd, apparently through multiple Bcd
domains [(24,26); see Figure 1A for a schematic diagram of
Bcd domains interacting with co-factors].
In this report, we use Bcd(A57–61), an inactive protein
on the hb-CAT reporter in S2 cells, as a tool to analyze
Figure 1. Exogenous dCBP switches the activity states of Bcd(A57–61) in S2 cells. (A) Shown is a schematic diagram of Bcd and its interacting domains with
co-factors. The homeodomain (residues 92–151) of the 489 amino acid Bcd protein is markedwith a black box and the two neighboring mutations discussed in this
report,A52–56andA57–61,areeachmarkedwithan‘X’.Theinteractioninformationinthisdiagramisbasedon(25)forSin3A,(24,26)forSAP18and(23)forCBP.
The diagram is not drawn to scale. (B) Shown are CAT assay results in S2 cells that were transfected with the reporter plasmid hb-CAT (1 mg), the indicated
amountsofeffectorplasmidsexpressingwtBcdorBcd(A57–61),with(+)orwithout()anothereffectorplasmid(5mg)expressingdCBP.FoldactivationbywtBcd
(at 1 mg transfected DNA) without exogenous dCBP was set to 100.
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regulating Bcd function. This mutant exhibits some special
properties. In particular, while it is inactive on the hb-CAT
reporter gene, it can activate another reporter gene, kni-CAT
(17). These and other ﬁndings suggest that the activity state
of this protein is intricately controlled, and we sought to gain
a better understanding of this mutant protein by focusing
on the roles of, and the interplay between, Bcd interacting
co-factors. In this report, we show that increased concentra-
tions of dCBP in S2 cells can switch this protein from an
inactive state to an active one on the hb-CAT reporter. We
further show that the C-terminal domain of Bcd(A57–61)
mediates such activity-rescuing function of dCBP. We provide
evidence demonstrating that, despite its normal DNA binding
ability in vitro, Bcd(A57–61) fails to occupy the hb enhancer
element in cells. High levels of dCBP in S2 cells restore the
ability of Bcd(A57–61) to access the hb enhancer element and
enable this Bcd derivative to recruit the GTFs TBP and TFIIB
to the target promoter. We also provide evidence suggesting
that dCBP may negatively affect the interaction between Bcd
and Sin3A in cells. Together, these results demonstrate that
dCBP plays an important role in regulating Bcd function in
a dCBP concentration-dependent manner. They suggest that
the opposing actions of positive and negative co-factors can
facilitate Bcd to switch between its active and inactive states
in a manner that is independent on Bcd concentration.
MATERIALS AND METHODS
Plasmid construction
Plasmids expressing Bcd derivatives were generated in two
steps as described previously (23). The bcd gene was ﬁrst
modiﬁed on pFY441, a pGEM3-based plasmid containing
wt bcd linked to the coding sequence of the hemagglutinin
(HA) tag, and then transferred to pFY442, a plasmid express-
ing HA-tagged wt Bcd from the Drosophila actin 5C promoter
(24).ForBcd(1–246;A57–61),thepGEM3-basedplasmidwas
pDF333 and the expression plasmid was pFD347. Reporter
genes and the effector plasmids pFY443 [Bcd(1–246)] and
pFY465 [Bcd(A57–61)] have been described previously
(14,24). The expression plasmids of wt and mutant dCBP
were kindly provided by Dr S. Smolik.
Transient transfection assays
Drosophila S2 cells were transfected with plasmids by the
calcium phosphate co-precipitation method as described by
Invitrogen. The total amount of DNA in each transfection
was adjusted to 10 mg by salmon sperm DNA. In order to
monitor the transfection efﬁciency, 1 mg control plasmid
pCopia-lacZ was co-transfected in each experiment, and
both CAT assays and western blot analyses were normalized
according to the b-galactosidase activity. CAT activity was
measured as previously described by using three independ-
ently transfected samples for each experiment (14). The pro-
tein levels of Bcd derivatives with or without dCBP were
detected by western blot using anti-HA antibody (1:500
ﬁnal dilution, Babco). Double-strand RNA against endogen-
ous dCBP in S2 cells was generated as described previously
(23), and the RNAi treatment did not affect the accumulation
of Bcd in S2 cells.
Gel shift assays
The hb enhancer probe for gel shift experiments was released
from a plasmid and ﬁlled-in with Klenow in the presence of
[a-
32P]dCTP as described previously (17). Wild-type Bcd and
its derivative used in these assays were expressed in vitro by
using the TnT quick-coupled transcription/translation system
(Promega). The experimental procedures and conditions for
gel shift assays were described previously (17).
Chromatin-immunoprecipitation (ChIP) assays
ChIP assays were performed according to Fu et al. (23). The
presence of Bcd, GTFs and acetylated histones at the hb
enhancer-core promoter region was detected by PCR using
primers hb-core5 and hb-CAT3 as described previously (23).
Co-immunoprecipitation (Co-IP)
Co-IP experiments were performed as described previously
(23). Brieﬂy, nuclear extracts prepared from S2 cells were
incubated with anti-HA antibody (1:100 ﬁnal dilution) in IP
buffer (20 mM Tris–HCl, pH 8.0, 160 mM MgCl2, 0.1%
Nonidet P-40 and 10% glycerol). The precipitated products
were resolved by SAS–PAGE gel and detected by western blot
using anti-Sin3A antibodies [kindly provided by Drs Lori Pile
and David Wassarman (27)]. Quantitation of the co-IP data
shown in Figure 5 was conducted as follows. The intensities of
input and co-IP Sin3A bands for each sample were measured
to obtain an intensity ratio of co-IP product over input. For
each experiment, the ratio for Bcd transfection alone (lane 4)
was arbitrarily set to 100 to allow comparison of data from
independent experiments.
RESULTS
High levels of dCBP switch Bcd(A52–61) to an active
state
Our previous transfection experiments in S2 cells have shown
that Bcd(A57–61) has a strengthened self-inhibitory function
and is nearly completely inactive on the hb-CAT reporter
gene (17,25). This mutant protein is stably accumulated in
cells (25), suggesting that its inability to activate hb-CAT
reﬂects a distinct functional state of this protein rather than
its defects in protein stability. Unlike wt Bcd, which exhibited
a dose-dependent activation function in transfection assays
(Figure 1B, solid line), this mutant protein failed to activate
hb-CAT at all concentrations tested (Figure 1B, dashed line,
bottom). To determine whether high concentrations of the
co-activator dCBP might counteract the strengthened self-
inhibitory function and switch Bcd(A57–61) to an active
state, we conducted co-transfection experiments. In these
experiments, the ability of Bcd(A57–61) to activate hb-CAT
was measured in the presence or absence of dCBP exogen-
ously expressed from a transfected plasmid.
Our results showed that exogenous dCBP dramatically
rescued the activity of Bcd(A57–61) on hb-CAT, increasing
its activity by 29 to 110 fold depending on Bcd concentration
(Figure 1B, dashed line, top; also see Table 1). In the presence
of exogenous dCBP, the activity of Bcd(A57–61) at several
concentrations was higher than wt Bcd at its saturating con-
centrations (without exogenous dCBP). Table 1 lists the effect
Nucleic Acids Research, 2005, Vol. 33, No. 13 3987of dCBP on wt Bcd and Bcd(A57–61), further indicating that
Bcd(A57–61) responds to dCBP much more robustly than wt
Bcd does at all concentrations tested. As shown previously,
exogenous dCBP has no effect on reporter gene expression
in the absence of Bcd and does not alter the amount of Bcd
protein in cells (23). Together, these results suggest that
dCBP is a limiting co-factor for Bcd(A57–61) and is capable
of making this Bcd protein to switch between its inactive and
active states on the hb-CAT reporter in cells.
Rescue of Bcd(A56–61) activity by dCBP requires
the C-terminal domain of Bcd
It has been shown that Bcd and dCBP can physically interact
with each other (23). Deletion analysis further suggested
that the C-terminal half of Bcd plays an important role in
responding to the co-activator function of dCBP on the
hb-CAT reporter (23). To determine whether this domain
is required for mediating the activity-rescuing function of
dCBP, we analyzed the effect of exogenous dCBP on a
truncated derivative of Bcd, Bcd(1–246). Two versions of
Bcd(1–246), with either wt or the A57–61 mutation at its
N-terminus, were used in the experiments. As shown previ-
ously (23), the truncated derivative Bcd(1–246) responded to
dCBP modestly (Figure 2A). However, dCBP failed to rescue
the activity of the truncated, mutant protein Bcd(1–246;
A57–61) at all concentrations tested (Figure 2A). dCBP did
not affect the accumulated levels of the Bcd proteins
(Figure 2B). These results suggest that dCBP rescues the
activity of Bcd(A57–61) through the C-terminal domain
of Bcd.
Defect of Bcd(A57–61) in hb enhancer recognition
in cells but not in vitro
Bcd(A57–61) hasanormalability to bindtoasingleTAATCC
site when analyzed in vitro (25). To determine whether this
mutant protein might be defective in recognizing natural
enhancer elements that contain multiple Bcd binding sites,
we conducted gel shift studies using the hb enhancer element.
As shown previously (17), wt Bcd bound to this enhancer
element in a cooperative manner, forming protein–DNA
complexes that contained multiple Bcd molecules (Figure 3,
lanes 1–4). Our gel shift experiments using Bcd(A57–61)
showed that this mutant protein can bind to the hb enhancer
element in a manner comparable with the wt Bcd protein
Table 1. The effect of dCBP on wt Bcd and Bcd(A57–61)
DNA transfected (mg) Effect of dCBP (fold increase)
wt Bcd Bcd(A57–61)
0.01 17 58
0.03 19 72
0.1 4.8 110
0.3 4.7 61
1.0 7.5 29
Listed is the effect (fold increase) of dCBP on wt Bcd and Bcd(A57–61) in
activating the hb-CAT reporter gene in S2 cells. The amount of transfected
DNA refers to the plasmids expressing the Bcd derivatives. The data for wt
Bcd and Bcd(A57–61) are from Fu et al. (23) and Figure 1B, respectively.
Figure 2. Switch of Bcd(A57–61) activity states by dCBP requires Bcd C-terminal domain. (A) Shown are CAT assay results in S2 cells that were transfected with
the reporter plasmid hb-CAT (1 mg), the indicated amounts of effector plasmids expressing two different Bcd derivatives, with (+) or without () the effector
plasmid(5mg)expressingdCBP.ThetwoBcd derivativesareBcd(1–246), atruncatedBcdwitha wtN-terminus;Bcd(1–246;A57–61),a truncatedderivativewith
theA57–61mutationinitsself-inhibitorydomain.Foldactivationforeachassay,measuredbyCATactivity,isshowninthefigure.(B)Westernblotdatashowingthe
HA-tagged Bcd protein levels (1 mg transfected DNA) in the presence (+) or absence () of dCBP (5 mg transfected DNA).
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natural enhancer element, kni, in a cooperative manner similar
to the wt Bcd protein in vitro (data not shown). These results
further support our conclusion that the A57–61 mutation of
Bcd does not abolish the protein’s ability to recognize DNA
in vitro (25).
To further dissect the defects of Bcd(A57–61), thus helping
understand the mechanisms of the functional rescue by dCBP,
we carried out a ChIP analysis in cells. We compared the
occupancy of wt Bcd and Bcd(A57–61) at the hb-CAT
reporter. We speciﬁcally chose conditions in which Bcd
proteins were expressed at high levels to reveal functional
defects of the mutant Bcd that could not be overcome by
increased Bcd concentrations (also see Figure 1B for reporter
assay data). As shown previously (23), our ChIP experiments
detected a signiﬁcant occupancy of wt Bcd at the hb enhancer
element of the reporter gene [Figure 4B (a), lane 9]. In
contrast, Bcd(A57–61) failed to exhibit an occupancy above
background levels at the hb enhancer element in the same
ChIP assays [Figure 4B (a), lane 11]. Together, these results
suggest that Bcd(A57–61), despite its normal ability to bind
DNA in vitro, has a functional defect in accessing the hb
enhancer element in cells.
dCBP restores the occupancy of Bcd(A57–61)
at hb enhancer in cells
TodeterminewhetherdCBPcanaffecttheabilityofBcd(A57–
61) to access the hb-CAT reporter gene in cells, we conducted
ChIP experiments in the presence of exogenously expressed
dCBP (see Figure 4A for a schematic diagram of the reporter
gene). As shown by the ChIP data [Figure 4B (a), lanes 11 and
12], dCBP restored the occupancy of Bcd(A57–61) at the hb
enhancer element in cells [Figure 4B (a), lane 12]. Under the
conditions of high Bcd concentrations, dCBP had little effect
on wt Bcd (lanes 9 and 10) as shown previously (23).
Our ChIP experiments also revealed a restored occupancy
ofGTFs atthehb-CATreportercausedbyhighlevelsofdCBP.
In the absence of exogenous dCBP, Bcd(A57–61) failed to
enhance the occupancy of either TBP or TFIIB at the promoter
region [Figure 4B (b and c), compare lanes 7, 9 and 11]. In the
presence of exogenous dCBP, Bcd(A57–61) increased the
Figure 4. RestoredoccupancyofBcd(A57–61)andGTFsbyexogenousdCBP.(A)Shownisaschematicdiagramofthereportergene,markingthepromoterregion
(thin line) used for detection by PCR in ChIP assays. The diagram is not drawn to scale. (B) Shown are ChIP data from S2 cells that were transfected with plasmids
expressingthe indicatedeffectors[dCBPproteins,5 mg; Bcd(A57–61),1 mg]and the hb-CATreporterplasmid(1 mg). Antibodiesusedfor ChIPassays were:HA to
detect HA-tagged Bcd (panel a), TBP (panel b), TFIIB (panel c), acetyl-H3 (panel d) and H4 (panel e). Lanes 1–6 show input controls, which represent the PCR
product of 1% of the total isolated DNA used in the ChIP assays.
Figure 3. Enhancer element binding by Bcd(A57–61) in vitro. Gel shift data
showing DNA binding to the hb enhancer element by wt Bcd (lanes 1–4)
and Bcd(A57–61) (lanes 5–7). Free probe is indicated by an arrowhead
(bottomright).IntheabsenceofBcd,therewerenoshiftedcomplexesdetected
(data not shown).
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experiments showed that dCBP increased the acetyl-H3 and
H4 levels at the reporter in the presence of either wt Bcd or
Bcd(A57–61) [Figure 4B (d and e), lanes 9–12]. In all the
cases, the effects of dCBP required the presence of Bcd or
its derivative (compare lanes 7 and 8), indicating that these
observed effects represent Bcd-dependent functions of dCBP.
Together, these results reveal not only a restored occupancy,
caused by increased dCBP levels in cells, of Bcd(A57–61) at
the hb-CAT reporter but also an elevated recruitment of GTFs
and an increased histone acetylation level at the reporter.
dCBP may negatively affect Bcd–Sin3A
interaction in cells
As further detailed in Discussion (below), several models are
consistentwith ourﬁnding thathighlevelsofdCBPcanrestore
activity to Bcd(A57–61). For example, it is possible that dCBP
and Sin3A may compete for Bcd interaction, thus representing
antagonistic forces to inﬂuence Bcd function. To determine
whether the interaction between Bcd and Sin3A might be
affected by dCBP, we conducted co-IP experiments in cells
with altered dCBP levels. To reduce cellular levels of dCBP,
we used an RNAi approach, which has been shown to specif-
ically affect Bcd activity without altering the amount of
Bcd in cells (23). We used exogenously expressed dCBP to
increase its cellular levels. As shown in our co-IP experiments
(Figure 5A), the amount of Sin3A precipitated by Bcd was
increased by dCBP RNAi treatment (lane 6) and marginally
affected by dCBP overexpression (lane 5). Figure 5B shows
the quantitation of the data from three independent experi-
ments (relative amounts of co-IP Sin3A for lanes 4, 5 and 6
are 100, 87 ± 16 and 276 ± 88, respectively). These results
suggest that dCBP may negatively affect the interaction
between Bcd and Sin3A. The modest effect of dCBP on
Sin3A–Bcd interaction suggests that such an antagonistic
effect may represent only one of the several individually
weak mechanisms by which dCBP rescues the activity of
Bcd(A57–61) (see Discussion for further details).
The HAT-deficient mutant dCBP can partially rescue
Bcd(A57–61) activity
Our previous experiments have shown that dCBP can increase
the activity of wt Bcd through both HAT-dependent and
-independent mechanisms (23). A HAT-independent action of
dCBP suggests a structural role of this protein in regulating
Bcd activity, a suggestion consistent with the observed neg-
ative effect of dCBP on Bcd-Sin3A interaction (Figure 5). To
speciﬁcally determine whether the HAT activity of dCBP is
required for its ability to restore function to Bcd(A57–61) on
the hb-CATreporter,weusedaHAT-deﬁcientmutant ofdCBP
(28); both wt dCBP and this mutant protein are accumulated to
similar levels when expressed in S2 cells (23). As shown in
Figure 6, this mutant dCBP increased partially the activity of
wt Bcd on the hb-CAT reporter [lanes 4–6; also see (23)]. It
also rescued, though with a reduced efﬁciency, the activity of
Bcd(A57–61) on the hb-CAT reporter (lanes 7–9). Together,
these results suggest that dCBP can play an enzyme activity-
independent role in rescuing the activity of Bcd(A57–61) on
the hb-CAT reporter in cells.
Figure 5. Interaction between Bcd and Sin3A may be affected by dCBP.
(A) The interaction between HA-tagged Bcd and the endogenous Sin3A in
S2 cells was detected by a co-IP analysis (see Materials and Methods for
details). Sin3A co-precipitated by anti-HA antibodies was detected by western
blot usinganti-Sin3Aantibodies.S2cellswereeither transfected(+) ornot()
with the indicated plasmids expressing HA-Bcd (1 mg) and dCBP (5 mg), and
hadeitherbeensubject(+)ornot()todCBPRNAitreatment(25mgdsRNA).
In this figure, lanes 1–3 are controls showing that no Sin3A was precipitated
in the absence of HA-Bcd. Input represents one-tenth of total nuclear extract
used in the co-IP assay as described previously (23). (B) The relative amounts
of the co-IP Sin3A product in three independent experiments were quantified
(seeMaterialsandMethods)andtheresultsareshown(mean ± SD);alllanesin
this graph correspond to those in (A).
Figure 6. HAT-deficient dCBP can partially rescue the activity of Bcd(A57–
61). Shown are CAT assay results in S2 cells that were transfected with the
reporter plasmid hb-CAT (1 mg), the effector plasmids (1 mg) expressing the
indicated Bcd proteins, with (+) or without () another effector plasmid
(5 mg) expressing dCBP. The increase of Bcd activity by wt and mutant dCBP
proteins is also indicated in the figure as fold increase. The exogenously
expressed wt and mutant dCBP proteins are accumulated at similar levels
in S2 cells as described previously (23).
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As a molecular morphogen, Bcd can undergo switches, in
a concentration-dependent manner, between its active and
inactive states in activating transcription of its target genes.
The experiments described in this report suggest another
mechanism that can facilitate on–off switches of Bcd activity
in a Bcd concentration-independent manner. In particular,
the mutant Bcd(A57–61) is incapable of activating the
hb-CAT reporter gene in S2 cells at all concentrations tested
(Figure 1B). The inability of this mutant Bcd to activate the
hb-CAT reporter reﬂects a distinct functional state of this
protein rather than its defects in protein stability. In fact,
this same mutant protein is only modestly weaker than the
wt protein on another reporter gene, kni-CAT, which contains
the Bcd-responsive kni enhancer element (17). These and
other results suggested that the A57–61 mutation may cause
its functionally inactive state on hb-CAT by more efﬁciently
interacting with a co-repressor protein(s), such as Sin3A and
its associated complex(es) (24,25). The experiments described
in this report show that increased concentrations of dCBP
can restore activity to Bcd(A57–61) on the hb-CAT reporter
in cells. These results suggest that the opposing actions of
positive and negative co-factors can facilitate Bcd to switch
between its active and inactive states in a manner that is Bcd
concentration-independent.
Although Bcd(A57–61) can bind to both a single site and
natural enhancer elements in vitro, it is unable to access the
hb enhancer element in cells (Figures 3 and 4). These results
suggest that the DNA binding defect of this mutant protein
is only manifested in a cellular context. This notion is con-
sistent with our ﬁnding that the PAH domains of Sin3A do
not exhibit any increased ability to reduce DNA binding by
Bcd(A57–61) in vitro when compared with wt Bcd (data not
shown) (25). We propose that other co-repressors or those that
are associated with Sin3A, such as the HDACs, can reduce the
ability of Bcd to access a natural enhancer in cells. It is pos-
sible that the enzymatic HDAC activity that is more stably
associated with Bcd(A57–61) makes it unable to negotiate
with histones for accessing DNA. It is also possible that a
more stable Bcd-co-repressor complex may sterically hinder
the interaction between Bcd(A57–61) molecules and prevent
cooperative binding to the enhancer element in cells.
The most striking ﬁnding of this report is that high levels
of dCBP can switch Bcd(A57–61) from its inactive state
to an active one on the hb-CAT reporter in cells. Our ChIP
data further show that dCBP increases both the ability of
Bcd(A57–61) to access the hb enhancer element in cells and
the occupancy of GTFs at the reporter promoter (Figure 4B).
How does dCBP switch the activity states of Bcd(A57–61) on
hb-CAT in cells? Since Bcd and dCBP can physically interact
with each other through multiple domains (23) (Figure 1A),
it is possible that dCBP may increase the DNA binding ability
of Bcd in cells by stabilizing the interaction between Bcd
molecules and thus enhancing its cooperativity. It is also pos-
sible that dCBP may physically compete with co-repressor
complexes in interacting with Bcd. Our co-IP results suggest
that dCBP may negatively affect the interaction between Bcd
and Sin3A in cells (Figure 5). dCBP could also play a role in
facilitating the interaction between Bcd and the transcription
machinery. For all these actions, dCBP may play a structural
(rather than enzymatic) role (Figure 6). Finally, the fact that
the HAT-defective mutant of dCBP does have a reduced abil-
ity to restore activity to Bcd(A57–61) (Figure 6) indicates
that its enzymatic activity has a positive role, possibly through
modiﬁcations of histones. It is likely that dCBP can affect the
Bcd(A57–61) activity through multiple mechanisms that may
be weak individually (Figures 5 and 6) but, when combined,
canleadtoa dramatic switch fromits inactive statetoanactive
one on the hb-CAT reporter in cells.
Currently, it is poorly understood how precisely Bcd activ-
ates transcription. Previous studies suggest that much of its
activation function is conferred by the C-terminal portion of
Bcd (16,29). This portion of the protein contains several
domains, including the acidic, glutamine-rich and alanine-
rich domains, that are characteristic of activation domains
capable of interacting with components of the transcription
machinery (16,29–31). Interestingly, the alanine-rich domain
previously thought to play an activation role was shown
recently to exhibit an inhibitory function instead (32). The
C-terminal domain of Bcd can also interact with dCBP (23),
and our results show that this domain is responsible for medi-
ating the activity-switching function of dCBP (Figure 2).
Although much of the activation function of Bcd is provided
by its C-terminal domain, the N-terminal portion of the pro-
tein also contains some activation function. Studies have
shown that Bcd(1–246), a derivative lacking the entire C-
terminal portion of Bcd, can rescue the bcd
 phenotype
when expressed at high levels (33). These results suggest
that Bcd can achieve its activation function through multiple
domains presumably by interacting with different proteins,
including co-activators and components of the transcription
machinery. The results described in this report further support
the importance of dCBP in facilitating activation by Bcd.
Bcd is a morphogenetic protein whose behavior can be
regulated not only by its own concentration but also by the
enhancer architecture (17). Our recent experiments show that,
on the kni and hb enhancer elements, the N-terminal domain of
Bcd is preferentially used for either cooperative DNA binding
or self-inhibition, respectively (17). We propose that the inter-
action between Bcd molecules bound to the kni enhancer
element, through its N-terminal domain, can interfere with
its interaction with co-repressors, such as Sin3A. As described
in this report, co-activators such as dCBP and co-repressors
such as Sin3A can also functionally antagonize each other,
possibly by competing for Bcd interaction as part of the mech-
anisms (Figure 5). Bcd is more sensitive to the self-inhibitory
function on the hb enhancer element than on the kni enhancer
element (17); consistent with dCBP’s antagonistic role, dCBP
increases the activity of Bcd more robustly on the hb enhancer
element than on the kni enhancer element (23). However, the
interplay between positive and negative activities that regu-
late Bcd functions is probably far more complex than the
simple physical competition: as already discussed above,
dCBP can affect Bcd activity through multiple mechanisms
in both HAT-dependent and independent manners (Figure 6)
(23). Moreover, in the presence of exogenous dCBP, high
levels of Bcd(A57–61) cause a reduction in its activity on
the hb-CAT reporter in cells (Figure 1B), a reduction that is
not observed with wt Bcd (23), suggesting that the optimal
concentration ratio between Bcd and dCBP may vary depend-
ing on the strengths of the self-inhibitory function and
Nucleic Acids Research, 2005, Vol. 33, No. 13 3991interaction withco-repressors.Inaddition,highconcentrations
of dCBP can rescue the inactive derivative Bcd(A57–61), but
not another inactive derivative lacking the C-terminal por-
tion, Bcd(1–246; A57–61), suggesting that the Bcd–dCBP
interaction strength can also inﬂuence the balance between
positive and negative activities that regulate Bcd function.
The experiments described in this report suggest that an
activator’s function is subject to intricate controls by both
positive and negative activities in cells. A ﬁne balance
between these activities is critical for normal cellular and
developmental processes. Our transgenic experiments show
that both Bcd(A57–61), which has a strengthened self-
inhibitory function, and Bcd(A52–56), which has a weakened
self-inhibitory function, cause embryonic defects [(24) and
unpublished data]. In addition, embryos with reduced dCBP
activity exhibit defects in early expression patterns of a
Bcd target gene, even-skipped [(23) and Y. Wen, A. York
and J. Ma, unpublished data]. Finally, a recent study reveals
that mutations affecting SAP18, a component of the Sin3A-
HDACcomplex,canalterBcdfunctionandanteriorpatterning
in embryos (34). In addition to the co-factors discussed here
(Sin3A, dCBP and SAP18), Bcd likely has the ability to inter-
act with many other proteins, including not only regulatory
proteins but also components of the transcription machinery
(30,31). Precisely how all these different proteins harmoni-
ously regulate and facilitate the execution of Bcd functions
during development remains to be determined. Recent studies
have shown that the Bcd gradient in embryos possesses a
strikingly sophisticated ability to activate its target genes in
a precise manner (35–37). These ﬁndings further underscore
the need of intricate control mechanisms that facilitate Bcd to
switch between its active and inactive states in target gene
activation. Our studies suggest that on–off switches of
Bcd activity can be achieved not only in a Bcd concentration-
dependent manner but also in a Bcd concentration-
independent manner. It remains to be investigated whether
and how Bcd interacting proteins, including those yet to be
identiﬁed, participate in the precision control of target gene
activation during development.
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